Skip to content
10-Q

Quarterly Report

Panacea Life Sciences Holdings, Inc. PLSH

0001493152-23-016537

← back to feed
Filed
May 12, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 12, 2023 15.51M sh
Cash And Equivalents Q1 2023 · Mar 31, 2023 $73.23K
Cash And Equivalents Q1 2023 · Dec 31, 2022 $6.95K
Current Liabilities Q1 2023 · Mar 31, 2023 $15.89M
Current Liabilities Q1 2023 · Dec 31, 2022 $15.07M
Total Liabilities Q1 2023 · Mar 31, 2023 $22.36M
Total Liabilities Q1 2023 · Dec 31, 2022 $21.63M
Current Assets Q1 2023 · Mar 31, 2023 $5.95M
Current Assets Q1 2023 · Dec 31, 2022 $6.38M
Total Assets Q1 2023 · Mar 31, 2023 $18.56M
Total Assets Q1 2023 · Dec 31, 2022 $19.49M
Capex Q1 2023 · Mar 31, 2022 $9.73K
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$436.04K
Stockholders Equity Q1 2023 · Mar 31, 2022 $4.18M
Stockholders Equity Q1 2023 · Dec 31, 2021 $7.1M
Eps Basic restated Q1 2023 · Mar 31, 2022 −$0.16
Sga Expense Q1 2023 · Mar 31, 2022 $460.55K
Net Income Q1 2023 · Mar 31, 2022 −$2.78M
Operating Income Q1 2023 · Mar 31, 2022 −$1.65M
Gross Profit Q1 2023 · Mar 31, 2022 $100.38K
Cost Of Revenue Q1 2023 · Mar 31, 2022 $366.09K
Revenue Q1 2023 · Mar 31, 2022 $466.47K